Opinion|Videos|November 27, 2024

Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Overview

Key Takeaways

Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is managed with a combination of androgen deprivation therapy, chemotherapy, and novel agents like such as abiraterone and enzalutamide, aiming to improve survival outcomes while addressing the disease's high metastatic burden.